Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By James Swann
Inadequate program integrity contractor oversight and security vulnerabilities involving health information technology are among the top 10 management challenges facing the Department of Health and Human Services, according to a memorandum report from the HHS Office of Inspector General released Nov. 19.
The report, Top Management and Performance Challenges Facing the Department of Health and Human Services in Fiscal Year 2012, also identified curbing improper Medicare and Medicaid payments and detecting Medicare and Medicaid fraud as top challenges.
The Reports Consolidation Act of 2000 requires OIG to submit an annual report to HHS on top management challenges.
According to the report, program integrity contractors within the Centers for Medicare & Medicaid Services have often used inadequate data during their investigations, which has led to potential Medicare and Medicaid overpayments.
“The integrity contractors rely heavily on data to conduct program integrity tasks, yet OIG work has found significant limitations in the Medicare and Medicaid data available to contractors,” the report said.
For example, Medicaid Integrity Contractors rely on claims data from the Medicaid Statistical Information System to perform their investigations, but OIG reviews have determined that MSIS data “are not complete, accurate or timely and do not capture all data elements that can assist in the detection of fraud, waste and abuse,” the report said.
OIG said CMS has not provided adequate management or oversight of contractors. However, CMS has made progress in working with its contractors, including beginning a project to improve MSIS data and increasing the amount of data it collects on contractor performance, the report said.
In addition to contractor oversight issues, OIG identified problems associated with implementing HIT, including protecting patient data in electronic health records.
Although EHRs can benefit patient health by providing a central collection point for information, they “can also be used to fabricate information, generating improper payments and corrupting patients' records with inaccurate and potentially dangerous information,” it said.
HHS has made improvements in protecting patient information contained in EHRs, such as educating physicians on protecting patient records, but HHS needs to play a more active role, OIG said.
To help secure EHRs, HHS should “provide additional guidance on information technology standards and best practices that the health care industry should adopt for EHRs,” OIG said.
The OIG report said HHS faces numerous challenges in detecting Medicare and Medicaid fraud. It cited problems with:
• CMS's effective use of enrollment and payment suspension authorities to deter fraudulent providers. OIG said CMS should pay close attention to independent diagnostic testing facilities and comprehensive outpatient rehabilitation facilities looking to enroll in Medicare, as the two groups have had a history of not complying with some basic Medicare requirements;
• its ability to oversee an increased use of data analytics;
• its maintenance of up-to-date and accurate data;
• its detection of fraud associated with private plans delivering Medicare and Medicaid benefits. OIG said CMS should continue to review Medicare Part D and Medicare Advantage plans to ensure they are meeting program integrity standards; and
• its effective exclusion of individuals and entities from federal health care programs.
OIG also said oversight of the Food and Drug Administration was a top management challenge.
Previous OIG reviews identified several vulnerabilities within FDA, OIG said, including inadequate monitoring of drug and device manufacturers to ensure that products are not being marketed for off-label use.
OIG also said FDA should improve its oversight of drug and device regulatory decisions.
“For example, the OIG found weaknesses in FDA's management of internal scientific disagreements related to regulatory decisions for medical devices under agency review,” the report said.
OIG said it will continue to evaluate FDA oversight of risk evaluation and management strategies used by drug and device sponsors.
The OIG Top Management Challenges list is at http://www.hhs.gov/afr/hhs_agency_financial_report_fy_2012-oai.pdf. Type in “Top Management and Performance Challenges” in the pdf search box to the find the report.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)